AbbVie vs Eli Lilly: Which Dividend Stock Wins for the Next Decade?
A comparative analysis of AbbVie (ABBV) and Eli Lilly (LLY) as dividend stocks. AbbVie has rewarded shareholders for 54 straight years, while Eli Lilly focuses on reinvesting for growth.
Key Numbers
According to Barchart, a comparative analysis between AbbVie (ABBV) and Eli Lilly (LLY) reveals a clear difference in dividend strategy. AbbVie continues to reward shareholders with dividends for the 54th consecutive year, making it an attractive option for income investors. In contrast, Eli Lilly focuses on reinvesting its earnings to fund growth, which could lead to higher capital returns over the long term.
Dividend Strategy
AbbVie (ABBV)
- Stable Dividend History: Has paid dividends for 54 consecutive years.
- Dividend Yield: Relatively higher compared to Eli Lilly.
- Growth: Increases dividends annually, but at a slower growth rate.
Eli Lilly (LLY)
- Reinvestment: Prefers to reinvest earnings into R&D and expansion.
- Dividend Yield: Currently low.
- Growth: Focuses on capital appreciation rather than cash dividends.
Which Is Better for the Next Decade?
The choice depends on investor goals. If you seek regular income and stability, AbbVie may be the better pick. If you prefer long-term capital growth, Eli Lilly could be more attractive. Both stocks have strong fundamentals in the healthcare sector.
Frequently Asked Questions
Found this useful? Share it